The field of radiochemistry is moving toward exclusive use of automated synthesis modules for production of clinical radiopharmaceutical doses. Such a move not only comes with many advantages but also presents radiochemists with the challenge of re‐configuring synthesis modules for production of radiopharmaceuticals that require non‐conventional radiochemistry while maintaining full automation. Herein, we continue our series of articles showcasing the versatility of the Tracerlab FX synthesis modules by presenting straightforward, fully automated methods for preparing a range of carbon‐11 labeled radiopharmaceuticals using a Tracerlab FXC‐Pro. Strategies for production of [11C]acetate, [11C]carfentanil, [11C]choline, [11C]3‐amino‐4‐[2‐[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile ([11C]DASB), (+)‐a‐[11C]dihydroterabenazine ([11C]DTBZ), [11C]flumazenil ([11C]FMZ), meta‐hydroxyephedrine ([11C]HED), [11C]methionine, [11C]PBR28, [11C]Pittsburgh Compound B ([11C]PiB), 1‐[11C]methylpiperidin‐4‐yl propionate ([11C]PMP), and [11C]raclopride are presented.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: